Evidence map›Paper›PMID 41599753›Full record

ReviewPharmaceuticals (Basel, Switzerland)2026

Synergistic Effects of Plant Polysaccharides and Probiotics: A Novel Dietary Approach for Parkinson's Disease Intervention.

Ye Jin, Lu Wang, Ruiting Lin, Jing He, Da Liu, Yang Liu, Yongzhi Deng

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ye JinSchool of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China.
Lu WangSchool of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China.
Ruiting LinSchool of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China.
Jing HeSchool of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China.ORCID 0009-0009-2084-8627
Da LiuSchool of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China.
Yang LiuSchool of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China.ORCID 0009-0007-1449-2498
Yongzhi DengSchool of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China.

Funding

the Jilin Province Science and Technology Development Plant Grant No. 20230204019YYthe Jilin Provincial Development and Reform Commission Project Grant No. 2023C027-3the National Natural Science Foundation of China Grant Nos. 82003985, 81973712, and 82004030the Undergraduate Innovation and Entrepreneurship Proiects Grant Nos, S202410199012, S202410199095X, andS202510199023
6 · The paper itself

Abstract

Parkinson's disease (PD), the second most common neurodegenerative disorder globally, relies primarily on dopamine replacement therapy for conventional treatment. This approach fails to reverse core pathological processes and is associated with long-term side effects. Recent research on the microbiota-gut-brain axis (MGBA) has revealed that PD pathology may originate in the gut, forming a vicious cycle from the gut to brain through α-synuclein propagation, gut dysbiosis, intestinal barrier disruption, and neuroinflammation. This offers a novel perspective for managing PD through dietary interventions that modulate the gut microbiome. However, single probiotic or prebiotic interventions show limited efficacy. This review systematically introduces the novel concept of "synbiotics combining medicinal plant polysaccharides with probiotics," aiming to integrate traditional "medicinal food" wisdom with modern microbiome science. The article systematically elucidates the pathological mechanisms of MGBA dysfunction in PD and the intervention mechanisms of probiotics and emphasizes the structural and functional advantages of medicinal plant polysaccharide as superior prebiotics. The core section delves into the multifaceted synergistic mechanisms between these two components: enhancing probiotic colonization and vitality, optimizing microbial metabolic output, synergistically reinforcing the intestinal and blood-brain barriers, and jointly regulating immune and neuroinflammation. This approach targets the MGBA to achieve multi-level intervention for PD.

Indexed as

gut microbiotamicrobiota-gut-brain axisParkinson’s diseaseplant polysaccharidesprobiotic

Identifiers

PMID41599753
PMCPMC12844740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.